Natera Announces Publication of Multi-Center Study Validating Signatera’s Ability to Predict Recurrence in Esophageal and Gastric Cancers

Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time was strongly associated with disease recurrence and poor prognosis AUSTIN, Texas, Dec. 9, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free…

Click here to view original post